Parkinsonism & Related Disorders
Volume 16, Issue 5 , Pages 334-337 , June 2010

Long term follow-up of Parkinson's disease patients with impulse control disorders

  • Melis Sohtaoğlu

      Affiliations

    • Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098 Istanbul, Turkey
    • ,
  • Derya Yavuz Demiray

      Affiliations

    • Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098 Istanbul, Turkey
    • ,
  • Gülay Kenangil

      Affiliations

    • Department of Neurology, Sisli Etfal Education and Research Hospital, Istanbul, Turkey
    • ,
  • Sibel Özekmekçi

      Affiliations

    • Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098 Istanbul, Turkey
    • Corresponding Author InformationCorresponding author. Tel./fax: +90 0212 588 3770.
    • ,
  • Ethem Erginöz

      Affiliations

    • Department of Community Medicine Center, Cerrahpasa Faculty of Medicine, Istanbul University, 34098 Istanbul, Turkey

Received 3 January 2010 ,Revised 8 February 2010 ,Accepted 11 February 2010.

References 

  1. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, et al. Association of dopamine agonist use with impulse control disorders in Parkinson's disease. Arch Neurol. 2006;63:969–973
  2. Pontone G, Williams JR, Bassett SS, March L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67:1258–1261
  3. Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S, et al. Prospective prevalence of pathological gambling and medication association in Parkinson's disease. Neurology. 2006;66:1750–1752
  4. Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008;14:89–99
  5. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21:524–529
  6. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol. 2004;17:393–398
  7. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatr. 2000;68:423–428
  8. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson's disease. Neurology. 2005;65:1570–1574
  9. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord. 2007;22:1757–1763
  10. Dodd ML, Klos KJ, Bower JH, Geda YE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377–1381
  11. Imamura A, Uitti RJ, Wszolek ZK. Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism Relat Disord. 2006;12:506–508
  12. Molina JA, Sainz-Artiga MJ, Fraile A, Jimenez-Jimenez FJ, Villanueva C, Ortí-Pareja M. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Mov Disord. 2000;15:869–872
  13. Kenangil G, Özekmekçi S, Sohtaoglu M, Erginöz E. Compulsive behaviors in patients with Parkinson's disease. Neurologist, in press.
  14. Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern MB, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord. 2008;23:75–80
  15. Fernandez HH, Friedman JH. Punding on L-Dopa. Mov Disord. 1999;14:836–838
  16. Molina JA, Sainz-Artiga MJ, Jimenez-Jimenez FJ, Fraile A, Villanueva C, Orti-Pareja M, et al. Pathological gambling in Parkinson's disease. Parkinsonism Relat Disord. 1999;5(Suppl. 1):S90
  17. Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B, et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989;12:375–383
  18. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992;42:1142–1146
  19. Fahn S, Elton RS. Members of the UPDRS development committee. Unified Parkinson's disease rating scale. In:  Fahn S,  Marsden CD,  Calne DB,  Goldstein M editor. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Publishers; 1987;p. 153–163
  20. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain. 2000;123:733–745
  21. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow?. Neurology. 1999;52:1227–1229
  22. Grosset K, Needleman F, Macphee G, Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord. 2004;19:1370–1374
  23. Galpern WR, Stacy M. Management of impulse control disorders in Parkinson's disease. Curr Treat Options Neurol. 2007;9:189–197
  24. Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol. 2006;21:203–209
  25. Bermejo PE. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. 2008;14:448–449
  26. Bach JP, Oertel WH, Dodel R, Jessen F. Treatment of hypersexuality in Parkinson's disease with carbamazepine–a case report. Mov Disord. 2009;24:1241–1242
  27. Voon V, Thomsen T, Miyasaki JM, de Souza M, Shafro A, Fox SH, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64:212–216
  28. Lawrence AJ, Blackwell AD, Barker RA, Spagnolo F, Clark L, Aitken MRF, et al. Predictors of punding in Parkinson's disease: results from a questionnaire survey. Mov Disord. 2007;22:2339–2345
  29. Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease:the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol. 2007;21:501–506
  30. Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord. 2008;14:28–32

☆ The review of this paper was entirely handled by an Associate Editor, Jonathan Carr.

PII: S1353-8020(10)00044-1

doi: 10.1016/j.parkreldis.2010.02.006

Parkinsonism & Related Disorders
Volume 16, Issue 5 , Pages 334-337 , June 2010

Article Tools